Pre‐prandial vs. post‐prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet‐treated or metformin‐treated Type 2 diabetes: a randomized controlled clinical trial

OBJECTIVE: Repaglinide is an oral anti-diabetic agent that has a short duration of action, and is suitable for preventing post-prandial rises in glucose levels. Targeting post-prandial glucose levels may lead to lower HbA(1c) levels and rates of hypoglycaemia than targeting pre-prandial glucose levels. RESEARCH DESIGN AND METHODS: In 42 centres, 193 drug-naive (n = 122) or metformin-treated (n = 71) individuals with Type 2 diabetes were …